
|Videos|June 29, 2021
Key Events in the FDA Pipeline During COVID-19
Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.
Advertisement
Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.
Landmon also discussed recent Emergency Use Authorizations that are crucial to highlight in the pipeline and the impact of "skinny labels" for generic products in the market.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
3
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
4
Adults With Schizophrenia Remain Stable When Transitioning from Atypical Antipsychotic to Cobenfy
5






































































































































